Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

4.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
4.0K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.0K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.9K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 vaccination status during pregnancy and preeclampsia risk: the pandemic-era cohort of the INTERCOVID consortium.

EClinicalMedicine·2026
Same author

Antioxidant and Photoprotective Capacity of Secondary Metabolites Isolated from <i>Pseudocyphellaria berberina</i>.

Molecules (Basel, Switzerland)·2025
Same author

Isolation, Chemical Characterization, and Antimicrobial Activity of Secondary Metabolites from <i>Pseudocyphellaria faveolata</i>.

Molecules (Basel, Switzerland)·2025
Same author

Postnatal growth of etiologically characterized preterm newborns according to gestational age at birth.

Pediatric research·2024
Same author

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.

Vaccine·2024
Same author

Presence of metabolic syndrome markers in very low birth weight ex-premature infants during early adolescence.

Journal of pediatric endocrinology & metabolism : JPEM·2024

Related Experiment Video

Updated: Mar 25, 2026

Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.4K

[Recommendations for palivizumab use. Update 2015].

, Silvia Fernández Jonusas1, Deleys Albas Maubett

  • 1Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, C1199ABD, Argentina. silvia.fernandez@hospitalitaliano.org.ar.

Archivos Argentinos De Pediatria
|February 26, 2016
PubMed
Summary

This updated guideline recommends monthly palivizumab injections for vulnerable infants during respiratory syncytial virus season. This monoclonal antibody is proven safe and effective in reducing hospitalizations for lower respiratory infections.

Keywords:
Monoclonal antibodiesPalivizumabRespiratory syncytial virusRespiratory tract infections

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Related Experiment Videos

Last Updated: Mar 25, 2026

Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.4K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Area of Science:

  • Pediatrics
  • Neonatology
  • Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants.
  • Premature infants, those with bronchopulmonary dysplasia, and congenital heart disease are at highest risk.
  • Previous recommendations from the Argentinean Pediatrics' Neonatal Committee (CEFEN) were published in 2007.

Purpose of the Study:

  • To update recommendations for the prevention of RSV lower respiratory infections.
  • To provide guidance on the use of palivizumab for high-risk infants.
  • To incorporate current scientific literature and epidemiological data.

Main Methods:

  • Systematic review of scientific literature on RSV prevention and palivizumab.
  • Analysis of epidemiological data for RSV season in Argentina.
  • Consensus development based on evidence and expert opinion.

Main Results:

  • Palivizumab, a monoclonal antibody, is recommended for high-risk infants.
  • A monthly intramuscular dose of 15 mg/kg is advised during the RSV season (April-September).
  • Evidence supports the safety, effectiveness, and reduction in hospitalization rates associated with palivizumab.

Conclusions:

  • Updated recommendations emphasize palivizumab prophylaxis for vulnerable populations during RSV season.
  • General preventive measures, including hand hygiene and family education, remain crucial.
  • The guidelines aim to reduce the burden of RSV-related hospitalizations in infants.